Effects of the polysaccharide nucleic acid fraction of bacillus calmette‑guérin on the production of interleukin‑2 and interleukin‑10 in the peripheral blood lymphocytes of patients with chronic idiopathic urticaria

Li,Na; Cao,Na; Niu,Yan‑Dong; Bai,Xiu‑Hui; Lu,Jie; Sun,Yu; Yu,Min; Sun,Li-Xin; Duan,Xin‑Suo

doi:10.3892/br.2013.130

Effects of the polysaccharide nucleic acid fraction of bacillus calmette‑guérin on the production of interleukin‑2 and interleukin‑10 in the peripheral blood lymphocytes of patients with chronic idiopathic urticaria

Authors:
- Na Li
- Na Cao
- Yan‑Dong Niu
- Xiu‑Hui Bai
- Jie Lu
- Yu Sun
- Min Yu
- Li-Xin Sun
- Xin‑Suo Duan
View Affiliations

Affiliations: Central Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China, Department of Dermatology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China
Published online on: July 4, 2013 https://doi.org/10.3892/br.2013.130
Pages: 713-718

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urticaria is one of the most frequent dermatoses and its prevalence in the general population is estimated to be ~20%, whereas a substantial percentage of the cases may be classified as chronic idiopathic urticaria (CIU). The inflammatory response presenting with spontaneous wheals exhibits pro‑inflammatory characteristics, involving a prominent role for lymphocytes with a mixed Th1/Th2 response in which interleukin (IL)‑2 and IL‑10 are prominently secreted by Th1 and Th2 cells, respectively. In CIU patients, it was demonstrated that IL‑10 production was elevated and IL‑2 reduced compared to controls. Therefore, inhibition of IL‑10 and promotion of IL‑2 production by the lymphocytes, indicating Th2 inhibition and Th1 promotion, may facilitate the treatment of CIU. Whether the polysaccharide nucleic acid fraction of bacillus calmette‑guérin (BCG‑PSN), which possesses multiple immunomodulatory properties, has that potential, remains to be elucidated. In this study, BCG‑PSN was used on lymphocytes isolated from CIU patients, with healthy donors used as controls. immunocytochemistry and ELISA were used to detect IL‑2 and IL‑10 production. It was demonstrated that the IL‑2 production by the lymphocytes in the CIU group was significantly lower compared to that in the healthy control group and it increased sequentially with the increase of the concentration of BCG‑PSN used. By contrast, the IL‑10 production by the lymphocytes in the CIU group was significantly higher compared to that in the healthy control group and decreased sequentially with the increase of the concentration of BCG‑PSN used. Thus, it may be concluded that the BCG‑PSN has the potential to promote IL‑2 and inhibit IL‑10 production in the lymphocytes of CIU patients, facilitating the treatment of CIU.

View Figures

View References

1	Di Campli C, Gasbarrini A, Nucera E, Franceschi F, Ojetti V, Sanz Torre E, Schiavino D, Pola P, Patriarca G and Gasbarrini G: Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci. 43:1226–1229. 1998.
2	Nagashima Y, Kako K, Kim JD and Fukamizu A: Enhanced histamine production through the induction of histidine decarboxylase expression by phorbol ester in Jurkat cells. Mol Med Rep. 6:944–948. 2012.
3	Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N, Lu Y and Kong S: Increased interleukin-9 and CD4⁺IL-9⁺T cells in patients with systemic lupus erythematosus. Mol Med Rep. 7:1031–1037. 2013.PubMed/NCBI
4	Greaves MW: Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 3:363–368. 2003. View Article : Google Scholar : PubMed/NCBI
5	Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 114:465–474. 2004. View Article : Google Scholar : PubMed/NCBI
6	Caproni M, Giomi B, Volpi W, Melani L, Schincaglia E, Macchia D, et al: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol. 114:284–292. 2005. View Article : Google Scholar : PubMed/NCBI
7	Piconi S, Trabattoni D, Iemoli E, et al: Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol. 128:59–66. 2002. View Article : Google Scholar : PubMed/NCBI
8	Du Q, Gu X, Cai J, Huang M and Su M: Chrysin attenuates allergic airway inflammation by modulating the transcription factors T-bet and GATA-3 in mice. Mol Med Rep. 6:100–104. 2012.PubMed/NCBI
9	Gu X, Zhou L, Du Q, Jiang D, Yang X, Ji X and Yin K: Hesperetin inhibits the maturation and function of monocyte-derived dendritic cells from patients with asthma. Mol Med Rep. 2:509–513. 2009.PubMed/NCBI
10	Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li M, Xing EH, Lan TF, Jiang MM, Yang N and Li WD: Ganoderma lucidum polysaccharides counteract inhibition on CD71 and FasL expression by culture supernatant of B16F10 cells upon lymphocyte activation. Exp Ther Med. 5:1117–1122. 2013.
11	Tang S, Zhao B, Zhang G, Liu L and Zhou T: Immune modulatory and therapeutic effect of BCG polysaccharides nucleic acid on perennial allergic rhinitis. J Clin Otorhinolaryngol. 19:345–346. 2005.(In Chinese).
12	Song NN, Wang BX, Shi DZ, et al: Dimo-thylidioctyl ammonium bromide-BCG polysaccharide nucleic acid adjuvant enhanced the immunogenicity of a Mycobacterium tuberculosis subunit vaccine. Chin J Tuberc Res Dis. 32:513–516. 2009.(In Chinese).
13	Luo Y, Wang B, Hu L, et al: Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis mice. Vaccine. 27:6179–6185. 2009. View Article : Google Scholar : PubMed/NCBI
14	Li Q, Yu H, Zhang Y, et al: Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand J Immunol. 73:568–576. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhu B, Qie Y, Wang J, et al: Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm. 66:318–326. 2007. View Article : Google Scholar : PubMed/NCBI
16	Luo Y, Jiang W, Da Z, et al: Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule. Scand J Immunol. 75:293–300. 2012. View Article : Google Scholar : PubMed/NCBI
17	Grattan CEH and Humphreys F; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. 157:1116–1123. 2007. View Article : Google Scholar : PubMed/NCBI
18	Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH, Greaves MW, Henz BM, et al: EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 61:321–331. 2006. View Article : Google Scholar : PubMed/NCBI
19	Henz BM and Zuberbier T: Most chronic urticaria is food-dependent, and not idiopathic. Exp Dermatol. 7:139–142. 1998. View Article : Google Scholar : PubMed/NCBI
20	DeLong KL, Culler Sd, Saini SS, Beck LA and Chen SC: Annual direct and indirect care costs of chronic idiopathic urticaria. Arch Dematol. 144:35–39. 2008. View Article : Google Scholar : PubMed/NCBI
21	Tong LJ, Balakrishnan G, Kochan JP, Kinet JP and Kaplan AP: Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol. 99:461–465. 1997. View Article : Google Scholar : PubMed/NCBI
22	Gruber BL, Baeza M, Marchese MJ, Agnello V and Kaplan AP: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol. 90:213–217. 1988. View Article : Google Scholar : PubMed/NCBI
23	Xiong C, Li Q, Lin M, et al: The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial. J Oral Pathol Med. 38:551–558. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hu J and Chen H: The effect of BCG-PSN on T-cell subsets and cytokines in vernal conjunctivitis. J Huazhong Univ Sci Technolog Med Sci. 22:77–79. 2002. View Article : Google Scholar : PubMed/NCBI
25	Du Toit G, Prescott R, Lawrence P, Johar A, Brown G, Weinberg EG, et al: Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria. Ann Allergy Asthma Immunol. 96:341–344. 2006.PubMed/NCBI
26	Kidd P: Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 8:223–246. 2003.PubMed/NCBI
27	Morgan DA, Ruscetti FW and Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 193:1007–1008. 1976. View Article : Google Scholar : PubMed/NCBI
28	Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR and Reiner SL: Helper T cell differentiation is controlled by the cell cycle. Immunity. 9:229–237. 1998. View Article : Google Scholar : PubMed/NCBI
29	Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, et al: Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood. 94:2880–2889. 1999.PubMed/NCBI
30	Moore KW, O’Garra A, de Waal Malefyt R, Vieira P and Mosmann TR: Interleukin-10. Annu Rev Immunol. 11:165–190. 1993. View Article : Google Scholar : PubMed/NCBI
31	Buelens C, Willems F, Delvaux A, Piérard G, Delville JP, Velu T and Goldman M: Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol. 25:2668–2672. 1995. View Article : Google Scholar : PubMed/NCBI